SN BioScience announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial. This achievement follows the designation of SNB-101 as an orphan drug for small cell lung cancer in 2023 and its Fast Track designation in 2024.
CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, announced that Jan Case has joined the Company as Chief Operating Officer.
Genesis Medtech is proud to announce that iReach Omnia, the world's first powered stapler with 90° articulation capability, has been approved for market release in China by the National Medical Products Administration (NMPA).
Orthogon Therapeutics, a developer of novel antiviral medicines, announced the closing of an oversubscribed financing round, exceeding its $5M target and bringing total funding to over $25M. This funding will accelerate the development of its first-in-class treatments for managing BK virus reactivation in transplant patients.
GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced that its Life Sciences subsidiary, GenScript, has introduced a next generation DNA purification platform:
Vista, a leader in intelligent MRI acquisition software, announced two-year clinical results showing Vista Cardiac significantly improves workflow efficiency, ensures high-quality and consistent imaging, and scales cardiac MRI (CMR) programs to expand access to more patients.
Bruker Corporation announced the launch of the Dimension Nexus™ atomic force microscope (AFM). Dimension Nexus is the newest addition to the industry-leading Dimension® AFM product line, which has had more than 4600 systems installed around the world.
Medtronic plc a global leader in healthcare technology, announced U.S. Food and Drug Administration (FDA) clearance for its new InPen™ app featuring missed meal dose detection, paving the way for the launch of its Smart MDI system with the Simplera™ continuous glucose monitor (CGM).
Jazz Pharmaceuticals plc announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
Byondis B.V., an independent clinical stage biopharmaceutical company creating innovative targeted medicines for patients with cancer, announces the appointment of Louis Denis, M.D. as Chief Medical Officer. Dr. Denis brings more than 30 years of clinical development leadership and oncology expertise to Byondis.